Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 595-604

  Sun, Yulin ^a   Gao, Guangzhou ^b,c   Cai, Jianqiang ^a   Wang, Youliang ^e   Qu, Xiuhua ^c   He, Lidong ^c   Liu, Fang ^a   Zhang, Yangjun ^d   Lin, Kaixuan ^b   Ma, Shouzhi ^a   Yang, Xiao ^e   Qian, Xiaohong ^d   Zhao, Xiaohang ^a,c  

^a CANCER HOSPITAL   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^c NAVY GENERAL HOSPITAL   (China)

^d BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^e BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; LIPOCORTIN 2; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANIMALS; ANNEXIN A2; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84874774516     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs372     Document Type: Article

References (50)

1. Jemal, A. et al. (2011) Global cancer statistics. CA. Cancer J. Clin., 61, 69-90.
2. Thompson Coon, J. et al. (2007) Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol. Assess., 11, 1-206.
3. El-Serag, H.B. (2011) Hepatocellular carcinoma. N. Engl. J. Med., 365, 1118-1127.
4. De Masi, S. et al. (2005) Screening for hepatocellular carcinoma. Dig. Liver Dis., 37, 260-268.
5. Marrero, J.A. et al. (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137, 110-118.
6. Malaguarnera, G. et al. (2010) Serum markers of hepatocellular carcinoma. Dig. Dis. Sci., 55, 2744-2755.
7. Dunn, B.K. et al. (2010) Molecular markers for early detection. Semin. Oncol., 37, 224-242.
8. Soulier, J.P. et al. (1986) A new method to assay des-gamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma. Gastroenterology, 91, 1258-1262.
9. Hirai, H. et al. (1992) Lectin affinity electrophoresis of alpha-fetoprotein. Increased specificity and sensitivity as a marker of hepatocellular carcinoma. J. Chromatogr., 604, 91-94.
10. Lok, A.S. et al. (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 138, 493-502.
11. Sharma, M.C. et al. (2007) The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr. Pharm. Des., 13, 3568-3575.
12. Lokman, N.A. et al. (2011) The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron., 4, 199-208.
13. Flood, E.C. et al. (2011) The annexin A2 system and vascular homeostasis. Vascul. Pharmacol., 54, 59-67.
14. Gerke, V. et al. (2002) Annexins: from structure to function. Physiol. Rev., 82, 331-371.
15. Bandorowicz-Pikula, J. et al. (2012) Do annexins participate in lipid messenger mediated intracellular signaling? A question revisited. Mol. Membr. Biol., 29, 229-242.
16. Emoto, K. et al. (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res., 21(2B), 1339-1345.
17. Qi, Y.J. et al. (2008) Proteomic identification of malignant transformationrelated proteins in esophageal squamous cell carcinoma. J. Cell. Biochem., 104, 1625-1635.
18. Alfonso, P. et al. (2008) Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J. Proteome Res., 7, 4247-4255.
19. Yao, H. et al. (2009) Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer, 65, 41-48.
20. Sharma, M.R. et al. (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol., 81, 146-156.
21. Zhao, P. et al. (2011) HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology, 54, 2012-2024.
22. Hollås, H. et al. (2006) Annexin A2 recognises a specific region in the 3'-UTR of its cognate messenger RNA. Biochim. Biophys. Acta, 1763, 1325-1334.
23. Dreier, R. et al. (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol., 110, 137-148.
24. Yu, G.R. et al. (2007) Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp. Mol. Med., 39, 641-652.
25. Kittaka, N. et al. (2008) Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur. J. Cancer, 44, 885-897.
26. Lim, S.O. et al. (2002) Proteome analysis of hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 291, 1031-1037.
27. Mohammad, H.S. et al. (2008) Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int. J. Oncol., 33, 1157-1163.
28. Frohlich, M. et al. (1990) Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. Mol. Cell. Biol., 10, 3216-3223.
29. Longerich, T. et al. (2011) Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol. Res. Pract., 207, 8-14.
30. Ji, N.Y. et al. (2009) Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int. J. Mol. Med., 24, 765-771.
31. Sun, Y. et al. (2008) Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J. Proteome Res., 7, 3847-3859.
32. Li, X. et al. (2005) Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics, 5, 3423-3441.
33. Edmondson, H.A. et al. (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer, 7, 462-503.
34. Hilpert, K. et al. (2007) Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. Nat. Protoc., 2, 1333-1349.
35. Hao, X.P. et al. (2001) Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res., 61, 8085-8088.
36. Wang, Y. et al. (2004) HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology, 39, 318-324.
37. Yoon, S.Y. et al. (2006) Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int. J. Oncol., 29, 315-327.
38. Feng, H. et al. (2010) Protein profile in HBx transfected cells: a comparative iTRAQ-coupled 2D LC-MS/MS analysis. J. Proteomics, 73, 1421-1432.
39. Glenney, J.R. Jr et al. (1985) Amino-terminal sequence of p36 and associated p10: identification of the site of tyrosine phosphorylation and homology with S-100. Proc. Natl. Acad. Sci. U.S.A., 82, 7884-7888.
40. Johnsson, N. et al. (1990) Structural analysis of p36, a Ca2+/lipid-binding protein of the annexin family, by proteolysis and chemical fragmentation. Eur. J. Biochem., 188, 1-7.
41. Hajjar, K.A. et al. (1994) An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem., 269, 21191-21197.
42. Kassam, G. et al. (1998) The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry, 37, 16958-16966.
43. Tsunezumi, J. et al. (2008) Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces. FEBS J., 275, 4810-4823.
44. Cuervo, A.M. et al. (2000) Selective degradation of annexins by chaperonemediated autophagy. J. Biol. Chem., 275, 33329-33335.
45. Wang, C.Y. et al. (2009) Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol. Biol. Cell, 20, 4153-4161.
46. Babiychuk, E.B. et al. (2002) Modulating signaling events in smooth muscle: cleavage of annexin 2 abolishes its binding to lipid rafts. FASEB J., 16, 1177-1184.
47. Tomonaga, T. et al. (2004) Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res., 10, 2007-2014.
48. Kulkarni-Kale, U. et al. (2005) CEP: a conformational epitope prediction server. Nucleic Acids Res., 33, W168-W171.
49. Giannelli, G. et al. (2003) Tissue remodelling in liver diseases. Histol. Histopathol., 18, 1267-1274.
50. Karsdal, M.A. et al. (2012) Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay and drug development technologies. doi:10.1089/adt.2012.474.